.Pharmacolibrary.Drugs.ATC.A.A10BD17 .Pharmacolibrary.Drugs.ATC.A.A10BD17| name: | MetforminAndAcarbose |
| ATC code: | A10BD17 | route: | oral |
| n-compartments | 1 |
Metformin and acarbose is a combination drug used in the management of type 2 diabetes mellitus, particularly to improve glycemic control when monotherapy is insufficient. Metformin decreases hepatic glucose production and improves insulin sensitivity, while acarbose inhibits intestinal alpha-glucosidases to delay carbohydrate absorption. This fixed-dose combination is approved for use in several countries.
No publication was found reporting combined pharmacokinetic parameters for metformin and acarbose as a fixed-dose combination in humans. Individual PK profiles are known: metformin is commonly described by a one-compartment oral model with rapid absorption, while acarbose has minimal systemic absorption. The following estimates are provided based on published data for individual drugs in adult type 2 diabetic patients under oral administration.
Scheen, AJ, & Lefèbvre, PJ (1995). Antihyperglycaemic agents. Drug interactions of clinical importance. Drug safety 12(1) 32–45. DOI:10.2165/00002018-199512010-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7741982
Jennings, PE (1997). Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus. Drugs & aging 10(5) 323–331. DOI:10.2165/00002512-199710050-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9143853